Eli Lilly (NYSE:LLY) has filed lawsuits against four telehealth platforms that the pharma giant alleges are selling compounded versions of its blockbuster GLP-1/GIP receptor agonist tirzepatide ...

For instance, Henry Meds sells what it claims is an oral version of tirzepatide, the active ingredient in Lilly’s drugs. But Lilly in the lawsuit argued the oral version “is an untested ...

(Reuters) -Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S. judge last month blocked pharmacies from making copies of ...

Tirzepatide, the active ingredient in Lilly's Zepbound and Mounjaro for Type 2 diabetes, was in shortage for two years until Dec. 19, 2024. The U.S. Food and Drug Administration required an end to ...

Lilly is suing Mochi Health, Henry Meds, Willow Health and Fella Health, claiming they are illegally selling compounded versions of tirzepatide. Lilly's suits argue that the knock-off tirzepatide ...

(Reuters) -Eli Lilly said on Wednesday it had sued four compounders for selling unapproved products containing tirzepatide, after a U.S. judge last month blocked pharmacies from making copies of its ...